E Fund CSI Innovative Drugs ETF(516080) Falls 1.89%, Absorbs 162 Million Yuan Over the Past 8 Days

NewTimeSpace News, as of 13:44 on May 18, 2026, E Fund Innovative Drug ETF (516080) fell 1.89%, with its latest quoted price at 0.62 yuan. Looking at a longer timeframe, as of May 15, 2026, E Fund Innovative Drug ETF gained 10.63% over the past year, ranking 1/7 among comparable funds in terms of increase. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 2.97%, with a trading volume of 46.4562 million yuan. Over a longer horizon, as of May 15, the ETF's average daily turnover over the past week stood at 81.7994 million yuan, ranking in the top 3 among comparable funds.

Regarding scale, E Fund Innovative Drug ETF's AUM increased by 26.3388 million yuan over the past week, achieving significant growth, with the new scale increment ranking 1/7 among comparable funds. (Data source: Wind)

In terms of share size, the latest share count of E Fund Innovative Drug ETF reached 2.510 billion units, hitting a one-year high and ranking 3/7 among comparable funds. (Data source: Wind)

From a net capital inflow perspective, E Fund Innovative Drug ETF experienced continuous net inflows for eight consecutive days, with the highest single-day net inflow of 45.4119 million yuan, totaling an inflow of 162 million yuan, and an average daily net inflow of 20.3117 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for E Fund Innovative Drug ETF on the previous trading day reached 1.0381 million yuan, and the latest margin balance stood at 45.0670 million yuan. (Data source: Wind)

As of May 15, E Fund Innovative Drug ETF's net value increased by 19.59% over the past two years, ranking first among comparable funds. In terms of return capability, as of May 15, 2026, since its inception, the ETF achieved a highest single-month return of 22.96%, a longest consecutive gaining streak of five months with a cumulative gain of 33.43%, and an average return of 5.62% during up months. As of May 15, 2026, the ETF's annualized excess return over its benchmark over the past two years was 3.20%, ranking 1/7 among comparable funds.

In terms of drawdown, as of May 15, 2026, E Fund Innovative Drug ETF's relative drawdown versus its benchmark since the beginning of the year was 0.05%, indicating relatively low drawdown risk among comparable funds.

In terms of fees, E Fund Innovative Drug ETF has a management fee rate of 0.15% and a custody fee rate of 0.05%, the lowest fee rates among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index, which E Fund Innovative Drug ETF tracks, is only 46.45 times, placing it at the 11.49th percentile over the past year—meaning the valuation is lower than that of over 88.51% of the time in the past year, indicating a historically low level.

E Fund Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main business involves innovative drug research and development as index constituents, in order to reflect the overall performance of listed company securities in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.